Skip to main content
Premium Trial:

Request an Annual Quote

Linda Avey Versus the New York Times

Over at her blog, Linda Avey, a co-founder of 23andMe who left the company last fall to start an Alzheimer's disease research foundation, is calling out the New York Times' Andrew Pollack. According to Avey, Pollack "has been digging around, looking for dirt and hoping to stir up controversy for a story he's apparently writing about the personal genetics industry." There's no article published yet in the Times – Pollack's newest piece discusses a failed drug trial for an Alzheimer's disease treatment – and Avey doesn't say in her post what Pollack is after. She does, however, admonish Pollack for attacking the "fledgling industry" and says that the goal of 23andMe is "to remove the barriers of access to [genetic] data." Pollack, she writes, could even benefit as these "data-empowered people … may just help lead us into a new age of personalized health." Avey didn't seem to mind the Times' coverage of 23andMe's spit parties, so this has the Daily Scan wondering what Pollack is working on.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.